Overview

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects with Type 2 Diabetes Mellitus (T2DM)

Status:
NOT_YET_RECRUITING
Trial end date:
2026-08-17
Target enrollment:
Participant gender:
Summary
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2 Diabetes Mellitusin.
Phase:
PHASE3
Details
Lead Sponsor:
Gan & Lee Pharmaceuticals.